Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (15727)	2/23/1998 8:06:00 PM
From: John O'Neill	Respond to of 32384

Henry, As a biochemist you must have an opinion about companies doing research on antibiotic resistant bacteria. I know this is not in LGND's bag, but , from my professional experience, I think this may be the most immediate threat/public concern in the biotech area at the present time. Companies in this area also have the advantage of a greater relationship between in vitro and in vivo research. The best I've found so far is MCDE..It's price appears to be artificially low due to one time market conditions (window for venture capital to sell). Do you have an opinion on this stock or a better one in this field.? They have over $4 cash per share for a stock selling a $8. A low cash burn with a dynamic research team. Comments appreciated John O